Better reporting of harms in randomized trials: An extension of the CONSORT statement

被引:1121
作者
Ioannidis, JPA
Evans, SJW
Gotzsche, PC
O'Neill, RT
Altman, DG
Schulz, K
Moher, D
机构
[1] Childrens Hosp Eastern Ontario, Res Inst, Chalmers Res Grp, Ottawa, ON K1H 8L1, Canada
[2] Univ Ioannina, Sch Med, GR-45110 Ioannina, Greece
[3] London Sch Hyg & Trop Med, London WC1, England
[4] Nord Cochrane Ctr, Copenhagen, Denmark
[5] US FDA, Rockville, MD 20857 USA
[6] Canc Res UK, Natl Hlth Serv, Ctr Stat Med, Oxford, England
[7] Family Hlth Int, Res Triangle Pk, NC 27709 USA
[8] Univ Ioannina, Fdn Res & Technol Hellas, Inst Biomed Res, Ioannina, Greece
关键词
D O I
10.7326/0003-4819-141-10-200411160-00009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In response to overwhelming evidence and the consequences of poor-quality reporting of randomized, controlled trials (RCTs), many medical journals and editorial groups have now endorsed the CONSORT (Consolidated Standards of Reporting Trials) statement, a 22-item checklist and flow diagram. Because CONSORT primarily aimed at improving the quality of reporting of efficacy, only 1 checklist item specifically addressed the reporting of safety. Considerable evidence suggests that reporting of harms-related data from RCTs also needs improvement. Members of the CONSORT Group, including journal editors and scientists, met in Montebello, Quebec, Canada, in May 2003 to address this problem. The result is the following document: the standard CONSORT checklist with 10 new recommendations about reporting harms-related issues, accompanying explanation, and examples to highlight specific aspects of proper reporting. We hope that this document, in conjunction with other CONSORT-related materials (www.consort-statement.org), will help authors improve their reporting of harms-related data from RCTs. Better reporting will help readers critically appraise and interpret trial results. Journals can support this goal by revising Instructions to Authors so that they refer authors to this document.
引用
收藏
页码:781 / 788
页数:8
相关论文
共 51 条
  • [1] The revised CONSORT statement for reporting randomized trials: Explanation and elaboration
    Altman, DG
    Schulz, KF
    Moher, D
    Egger, M
    Davidoff, F
    Elbourne, D
    Gotzsche, PC
    Lang, T
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) : 663 - 694
  • [2] [Anonymous], 1998, DETECTION NEW ADVERS
  • [3] [Anonymous], 1999, Common toxicity criteria manual: CTC
  • [4] The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)
    Bonhoeffer, J
    Kohl, K
    Chen, R
    Duclos, P
    Heijbel, H
    Heininger, U
    Jefferson, T
    Loupi, E
    [J]. VACCINE, 2002, 21 (3-4) : 298 - 302
  • [5] SEREVENT NATIONWIDE SURVEILLANCE STUDY - COMPARISON OF SALMETEROL WITH SALBUTAMOL IN ASTHMATIC-PATIENTS WHO REQUIRE REGULAR BRONCHODILATOR TREATMENT
    CASTLE, W
    FULLER, R
    HALL, J
    PALMER, J
    [J]. BRITISH MEDICAL JOURNAL, 1993, 306 (6884) : 1034 - 1037
  • [6] Cato A, 1987, Drug Inf J, V21, P3
  • [7] Empirical evidence for selective reporting of outcomes in randomized trials -: Comparison of Protocols to published articles
    Chan, AW
    Hróbjartsson, A
    Haahr, MT
    Gotzsche, PC
    Altman, DG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (20): : 2457 - 2465
  • [8] Laboratory data in clinical trials: A statistician's perspective
    Chuang-Stein, C
    [J]. CONTROLLED CLINICAL TRIALS, 1998, 19 (02): : 167 - 177
  • [9] Discussion sections in reports of controlled trials published in General medical journals
    Clarke, M
    Alderson, P
    Chalmers, I
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (21): : 2799 - 2801
  • [10] DEVELOPMENT OF A QUESTIONNAIRE FOR DETECTING POTENTIAL ADVERSE DRUG-REACTIONS
    CORSO, DM
    PUCINO, F
    DELEO, JM
    CALIS, KA
    GALLELLI, JF
    [J]. ANNALS OF PHARMACOTHERAPY, 1992, 26 (7-8) : 890 - 896